{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:00:39Z","timestamp":1772308839577,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ygyno.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T08:33:13Z","timestamp":1637051593000},"page":"154-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer"],"prefix":"10.1016","volume":"164","author":[{"given":"Kathy","family":"Matuszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"ten Kortenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Santry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kin-Ming","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byram W.","family":"Bridle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah K.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.11.006_bb0005","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0010","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1073\/pnas.87.17.6624","article-title":"A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin","volume":"87","author":"Good","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI12749","article-title":"Thrombospondins as matricellular modulators of cell function","volume":"107","author":"Bornstein","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00018-007-7486-z","article-title":"Thrombospondins in cancer","volume":"65","author":"Kazerounian","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0025","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2174\/138945008785909266","article-title":"Thrombospondins","volume":"9","author":"Lawler","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ygyno.2021.11.006_bb0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fphar.2015.00252","article-title":"Original insights on thrombospondin-1-related antireceptor strategies in cancer","volume":"6","author":"Jeanne","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0035","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/jcp.21281","article-title":"Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1","volume":"214","author":"Nunes","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/71517","article-title":"Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1","volume":"6","author":"Jimenez","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mvr.2007.04.007","article-title":"Thrombospondin-based antiangiogenic therapy","volume":"74","author":"Zhang","year":"2007","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/mt.2014.214","article-title":"Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas","volume":"23","author":"Choi","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9440(10)63319-6","article-title":"Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta","volume":"165","author":"Yee","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0060","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/0008-5472.CAN-08-2940","article-title":"A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR","volume":"69","author":"Ren","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0065","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-04-1900","article-title":"Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2006.04.003","article-title":"Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model","volume":"247","author":"Zhang","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0075","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/0008-5472.CAN-09-3094","article-title":"Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1","volume":"70","author":"Lee","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0080","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","article-title":"Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer","volume":"25","author":"Matuszewska","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0085","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fj.14-261636","article-title":"Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer","volume":"29","author":"Russell","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0090","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","article-title":"Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer","volume":"25","author":"Matuszewska","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0095","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/protein\/11.6.495","article-title":"High level expression and secretion of Fc-X fusion proteins in mammalian cells","volume":"11","author":"Lo","year":"1998","journal-title":"Protein Eng."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0100","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.284.5415.808","article-title":"Effects of angiogenesis inhibitors on multistage carcinogenesis in mice","volume":"284","author":"Bergers","year":"1999","journal-title":"Science."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"Rath","year":"2015","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.copbio.2009.10.010","article-title":"Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology","volume":"20","author":"Huang","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00063030-200822010-00002","article-title":"Fc-based cytokines\u202f: prospects for engineering superior therapeutics","volume":"22","author":"Jazayeri","year":"2008","journal-title":"BioDrugs."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0125","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0130","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-07-1530","article-title":"Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy","volume":"14","author":"Lee","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/asia.201801677","article-title":"Designing multivalent ligands to control biological interactions: from vaccines and cellular effectors to targeted drug delivery","volume":"14","author":"Arsiwala","year":"2019","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0140","doi-asserted-by":"crossref","first-page":"25659","DOI":"10.1073\/pnas.1902909116","article-title":"Mechanisms of noncanonical binding dynamics in multivalent protein-protein interactions","volume":"116","author":"Errington","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0145","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1242\/jcs.188946","article-title":"Ligand-induced growth and compaction of CD36 nanoclusters enriched in Fyn induces Fyn signaling","volume":"129","author":"Githaka","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/excr.1998.3936","article-title":"A simple immunomagnetic protocol for the selective isolation and long- term culture of human dermal microvascular endothelial cells","volume":"240","author":"Richard","year":"1998","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1535-7163.MCT-08-0864","article-title":"ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"8","author":"Greenaway","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0160","series-title":"Assay Guidance Manual. Bethesda (MD)","article-title":"Cell viability assays","author":"Riss","year":"2004"},{"key":"10.1016\/j.ygyno.2021.11.006_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines4030014","article-title":"Antibody-drug conjugates for cancer therapy","volume":"4","author":"Parslow","year":"2016","journal-title":"Biomedicines."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0170","first-page":"e51764","article-title":"Confocal microscopy reveals cell surface receptor aggregation through image correlation spectroscopy","volume":"138","author":"Parslow","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-1-62703-547-7_31","article-title":"Orthotopic, syngeneic mouse model to study the effects of epithelial-stromal interaction","volume":"1049","author":"Greenaway","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0180","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1158\/1535-7163.MCT-11-0402","article-title":"ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer","volume":"10","author":"Campbell","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1593\/neo.91880","article-title":"The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer","volume":"12","author":"Campbell","year":"2010","journal-title":"Neoplasia."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ygyno.2021.11.006_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nbt0298-153","article-title":"Improving protein therapeutics with sustained-release formulations","volume":"16","author":"Putney","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0200","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejpb.2004.10.006","article-title":"Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles","volume":"59","author":"Bilati","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0205","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009712","article-title":"The thrombospondins","volume":"3","author":"Adams","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0210","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1161\/ATVBAHA.113.301523","article-title":"Molecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36","volume":"33","author":"Klenotic","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nm0402-349","article-title":"Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor","volume":"8","author":"Volpert","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0220","doi-asserted-by":"crossref","first-page":"H1344","DOI":"10.1152\/ajpheart.01246.2008","article-title":"Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina","volume":"296","author":"Sun","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0225","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/ATVBAHA.111.242511","article-title":"CD36 ectodomain phosphorylation blocks thrombospondin-1 binding: structure-function relationships and regulation by protein kinase C","volume":"32","author":"Chu","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0230","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745274","article-title":"CD36 initiates the secretory phenotype during the establishment of cellular senescence","volume":"19","author":"Chong","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0235","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/aps.2011.108","article-title":"The impact of cellular senescence in cancer therapy: is it true or not?","volume":"32","author":"Zhang","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0240","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0945-053X(00)00107-4","article-title":"The cell biology of thrombospondin-1","volume":"19","author":"Chen","year":"2000","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0245","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2203\/dose-response.09-049.Reynolds","article-title":"Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer","volume":"8","author":"Reynolds","year":"2010","journal-title":"Dose-Response"},{"key":"10.1016\/j.ygyno.2021.11.006_bb0250","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/sj.cgt.7700938","article-title":"Endostatin therapy reveals a U-shaped curve for antitumor activity","volume":"13","author":"Tjin Tham Sjin","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0255","first-page":"7830","article-title":"Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms","volume":"61","author":"Miao","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0260","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11095-006-9173-4","article-title":"Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation","volume":"24","author":"Chen","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0265","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.celrep.2015.01.035","article-title":"Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2","volume":"10","author":"Keskin","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0270","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4161\/cam.28733","article-title":"Assembly, heterogeneity, and breaching of the basement membranes","volume":"8","author":"Glentis","year":"2014","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.ygyno.2021.11.006_bb0275","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.devcel.2011.07.001","article-title":"Pericytes: developmental, physiological, and pathological perspectives, problems, and promises","volume":"21","author":"Armulik","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ygyno.2021.11.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132644","article-title":"Experimental branch retinal vein occlusion induces upstream pericyte loss and vascular destabilization","volume":"10","author":"Dominguez","year":"2015","journal-title":"PLoS One"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821015997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821015997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:01:42Z","timestamp":1758772902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821015997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0090825821015997"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.11.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}